We are live on ! Find out more
MDGL icon

Madrigal Pharmaceuticals
MDGL

68 hedge funds and large institutions have $9.88M invested in Madrigal Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 30 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less funds holding

Funds holding: 75 → 68 (-7)

39% less capital invested

Capital invested by funds: $16.3M → $9.88M (-$6.43M)

57% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 30

58% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 12

Holders
68
Holders Change
-7
Holders Change %
-9.33%
% of All Funds
1.81%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
5
Increased
13
Reduced
30
Closed
12
Calls
$20K
Puts
–
Net Calls
+$20K
Net Calls Change
+$71K

Top Buyers

1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$330K
2
RFC
Russell Frank Company
Washington
+$57.5K
3
SG Americas Securities
SG Americas Securities
New York
+$35.5K
4
Citigroup
Citigroup
New York
+$11.2K
5
WS
Wedbush Securities
California
+$10.7K

Top Sellers

1
AFM
Anson Funds Management
Texas
-$348K
2
Goldman Sachs
Goldman Sachs
New York
-$284K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$159K
4
SBIA
Sheaff Brock Investment Advisors
Indiana
-$113K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$90K
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
26
RhumbLine Advisers
Massachusetts
$22K – – –
Group One Trading
27
Group One Trading
Illinois
$20K -$24.8K -2,972 -56%
New York State Common Retirement Fund
28
New York State Common Retirement Fund
New York
$20K – – –
Citigroup
29
Citigroup
New York
$20K +$11.2K +1,339 +135%
AllianceBernstein
30
AllianceBernstein
Tennessee
$19K – – –
AIG
31
American International Group
New York
$15K – – –
NFA
32
Nationwide Fund Advisors
Ohio
$14K – – –
Wells Fargo
33
Wells Fargo
California
$12K +$635 +76 +5%
WS
34
Wedbush Securities
California
$11K +$10.7K +1,286 New
BA
35
BlackRock Advisors
Delaware
$10K – – –
TSS
36
Two Sigma Securities
New York
$9K +$8.6K +1,030 New
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$7K -$90K -10,770 -93%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$7K -$50K -5,981 -88%
UBS AM
39
UBS AM
Illinois
$7K -$301 -36 -4%
State Board of Administration of Florida Retirement System
40
State Board of Administration of Florida Retirement System
Florida
$7K +$117 +14 +2%
CS
41
Credit Suisse
Switzerland
$5K -$2.66K -318 -35%
Creative Planning
42
Creative Planning
Kansas
$5K -$17 -2 -0.3%
RC
43
Roundview Capital
New Jersey
$5K – – –
Two Sigma Investments
44
Two Sigma Investments
New York
$4K -$82.9K -9,929 -96%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4K -$11.2K -1,338 -74%
HK
46
Horizon Kinetics
New York
$4K – – –
Principal Financial Group
47
Principal Financial Group
Iowa
$4K – – –
CG
48
Cutler Group
California
$4K +$393 +47 +9%
Morgan Stanley
49
Morgan Stanley
New York
$3K -$6.37K -763 -70%
ProShare Advisors
50
ProShare Advisors
Maryland
$3K -$501 -60 -16%
1
2
3 4

MDGL Hedge Fund Activity: Q1 2016 in Review

68 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2016, worth a combined $9.88M — down 39% from $16.3M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of MDGL and 5 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 13 added.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $330K. The largest seller was Anson Funds Management, exiting entirely with an estimated $348K sold.

  • 68 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2016, down from 75 in Q4 2015.
  • Funds reported $9.88M of Madrigal Pharmaceuticals stock for Q1 2016, down 39% quarter-over-quarter.
  • 5 funds opened new Madrigal Pharmaceuticals positions in Q1 2016 and 12 closed out, a net change of -7 holders.
  • The largest Madrigal Pharmaceuticals buyer in Q1 2016 was Jacobs Levy Equity Management, an estimated $330K added.
  • The largest Madrigal Pharmaceuticals seller in Q1 2016 was Anson Funds Management, an estimated $348K sold.

Based on aggregated 13F filings for Q1 2016.